ReviewNature reviews. Gastroenterology & hepatology2020
Primary biliary cholangitis: pathogenesis and therapeutic opportunities.
Review in Nature reviews. Gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06293378 (Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.), which is not on this map. Cited by 167 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.
Who cites it
167 citing papers in PubMed, 9 syntheses or guidelines pooled it, 296 citations in OpenAlex.
- Efficacy, symptoms, and safety of second-line PBC therapies: a network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Prevalence of Celiac Disease in Patients With Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.Liver international : official journal of the International Association for the Study of the Liver · 2025Pooled it
- Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.Digestive diseases and sciences · 2025Pooled it
- Bibliometric analysis of research on intestinal flora and primary biliary cholangitis published between 2004 and 2024 using VOSviewer and CiteSpace visualization.Frontiers in medicine · 2025Pooled it
- MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.Journal of gastroenterology · 2024Pooled it
- Pooled it
- Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.Journal of hepatology · 2021Pooled it
- Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.Hepatology international · 2023Trial
- Advances and perspectives in genetically encoded biosensors for biomarker detection and theranostic circuits.Synthetic and systems biotechnology · 2027Review
- Improved catalytic efficiency of P450 OleP for converting lithocholic acid into murideoxycholic and ursodeoxycholic acids through semi-rational and rational design.Synthetic and systems biotechnology · 2027Article
- Compositional and functional differences of gut microbiome and metabolome inform pathogenesis of cholestatic liver disease.Gut microbes · 2026Article
- Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective.Journal of gastroenterology and hepatology · 2026Review
- Label-Free Urinary Proteomics Uncovers Immune-Related Non-Invasive Biomarkers for Primary Biliary Cholangitis.International journal of molecular sciences · 2026Article
- The instructive scar - the dynamic role of extracellular matrix in biliary pathophysiology.Disease models & mechanisms · 2026Review
- Serum immunoglobulin G levels in patients with cirrhosis due to autoimmune hepatitis or other etiologies.European journal of gastroenterology & hepatology · 2026Article
- Melatonin Alleviates Graft Biliary Fibrosis by Inhibiting VIMAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cathepsin Z/X: Breaking Down the Known and Unknown.International journal of molecular sciences · 2026Review
- Novel Mechanistic Insights into Primary Biliary Cholangitis: From Pathogenesis to Mesenchymal Stem Cell-Mediated Repair.Biomedicines · 2026Review
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary biliary cholangitis is a chronic, seropositive and female-predominant inflammatory and cholestatic liver disease, which has a variable rate of progression towards biliary cirrhosis. Substantial progress has been made in patient risk stratification with the goal of personalized care, including early adoption of next-generation therapy with licensed use of obeticholic acid or off-label fibrate derivatives for those with insufficient benefit from ursodeoxycholic acid, the current first-line drug. The disease biology spans genetic risk, epigenetic changes, dysregulated mucosal immunity and altered biliary epithelial cell function, all of which interact and arise in the context of ill-defined environmental triggers. A current focus of research on nuclear receptor pathway modulation that specifically and potently improves biliary excretion, reduces inflammation and attenuates fibrosis is redefining therapy. Patients are benefiting from pharmacological agonists of farnesoid X receptor and peroxisome proliferator-activated receptors. Immunotherapy remains a challenge, with a lack of target definition, pleiotropic immune pathways and an interplay between hepatic immune responses and cholestasis, wherein bile acid-induced inflammation and fibrosis are dominant clinically. The management of patient symptoms, particularly pruritus, is a notable goal reflected in the development of rational therapy with apical sodium-dependent bile acid transporter inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.